 we report on our second quarter 2020 financial results and discuss our plans for the second half of the year. 
 we also provide an update on our ongoing efforts to initiate the first phase 3 trial for cytisinicline in the smoking cessation market, the ORCA-2 safety trial. 
 finally, we discuss the impact of the COVID-19 pandemic on smokers and why we believe cytisinicline will have a key role to play in aiding smokers to quit in the future.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 